Related Experiment Video
Updated: Jun 10, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes
Guillaume Ploussard1, Michaël Baboudjian2, Eric Barret3
1Department of Urology, La Croix du Sud Hospital, 52 bis, Chemin de Ribaute, 31130 Quint Fonsegrives, France.
The French Journal of Urology
|October 18, 2025
Summary
This 2025 update provides new prostate cancer (PCa) management guidelines. Key changes include advanced imaging like biparametric MRI and updated treatment options for various PCa stages, aiming to improve patient outcomes.
Area of Science:
- Urology
- Oncology
- Medical Imaging
Background:
- Prostate cancer (PCa) management requires continuous updates based on evolving diagnostic and therapeutic strategies.
- The French Urology Association's Oncology Committee (CCAFU) regularly reviews and synthesizes new evidence.
Purpose of the Study:
- To present a 2025 summary of updated recommendations for prostate cancer (PCa) management.
- To inform physicians about recent advancements in PCa diagnosis and treatment.
Main Methods:
- A systematic literature review was conducted by the CCAFU.
- The review covered diagnostic and therapeutic evolutions in PCa management from July 2024 to September 2025.
- Newly published references were evaluated for their level of evidence.
Main Results:
- Biparametric MRI is a viable alternative to multiparametric MRI for biopsy guidance, requiring high-quality imaging and expertise.
- Transperineal biopsy is recommended when technically feasible.
- Treatment options updated include whole-gland HIFU for intermediate-risk PCa, specific androgen deprivation therapy (ADT) durations for metastatic disease, and novel systemic therapies like enzalutamide and combination regimens (e.g., niraparib + abiraterone) for specific patient subgroups.
- Radioligand therapy ([177Lu]LuPSMA-617) and combination therapies (enzalutamide + radium-223) are proposed for advanced metastatic castration-resistant prostate cancer (mCRPC).
Conclusions:
- This 2025 summary of French recommendations aims to enhance the management of prostate cancer (PCa) patients.
- Physicians are encouraged to adopt these updated guidelines to stay current with the latest evidence-based practices.
Related Concept Videos
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...